Literature DB >> 24835028

Profiles of pregabalin and gabapentin abuse by postmortem toxicology.

Margareeta Häkkinen1, Erkki Vuori2, Eija Kalso3, Merja Gergov2, Ilkka Ojanperä2.   

Abstract

Pregabalin (PRG) and gabapentin (GBP) are used in the treatment of neuropathic pain and epilepsy, and PRG also in generalized anxiety disorder. There is increasing evidence that PRG possesses considerable abuse potential. PRG may have a higher addiction potential than GBP due to its rapid absorption and faster onset of action. Our objective is to estimate the proportion of all PRG- and GBP-related fatalities attributable to PRG and GBP abuse. We investigated all medico-legal death cases in Finland in which PRG or GBP was found in postmortem toxicology during 2010-2011. PRG was found in 316 cases and GBP in 43 cases. Drug abuse was associated with 48.1% of the PRG and 18.6% of the GBP findings. PRG poisoning accounted for 10.1% of all PRG cases and GBP poisoning for 4.7% of all GBP cases. In the drug abuser cases, PRG poisoning represented 19.1%, and GBP poisoning 12.5%. The median blood concentration of PRG was 15 mg/L in the abuser group and 5.8 mg/L in the other cases. For GBP, these concentrations were 12 mg/L and 8.3mg/L, respectively. In the PRG abuser group, 91.4% of cases showed concomitant opioid use, while in the rest of these cases neither alcohol nor opioids were detected, but other central nervous system acting drugs were found in each abuser case. In the GBP abuser group, 87.5% of cases showed concomitant opioid use. PRG abuse with high doses is increasingly common and can be fatal when combined with opioids.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Blood drug concentration; Drug abuse; Fatal poisoning; Gabapentin; Postmortem toxicology; Pregabalin

Mesh:

Substances:

Year:  2014        PMID: 24835028     DOI: 10.1016/j.forsciint.2014.04.028

Source DB:  PubMed          Journal:  Forensic Sci Int        ISSN: 0379-0738            Impact factor:   2.395


  27 in total

Review 1.  Abuse Potential of Pregabalin: A Systematic Review.

Authors:  Ole Schjerning; Mary Rosenzweig; Anton Pottegård; Per Damkier; Jimmi Nielsen
Journal:  CNS Drugs       Date:  2016-01       Impact factor: 5.749

2.  Prescribing medical cannabis in Canada: Are we being too cautious?

Authors:  Stephanie Lake; Thomas Kerr; Julio Montaner
Journal:  Can J Public Health       Date:  2015-04-30

Review 3.  Abuse and Misuse of Pregabalin and Gabapentin.

Authors:  Kirk E Evoy; Megan D Morrison; Stephen R Saklad
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

4.  An acute gabapentin fatality: a case report with postmortem concentrations.

Authors:  F Lee Cantrell; Othon Mena; Ray D Gary; Iain M McIntyre
Journal:  Int J Legal Med       Date:  2015-04-24       Impact factor: 2.686

5.  Pregabalin Use Among Users of Illicit Drugs: A Cross-Sectional Survey in Southern Germany.

Authors:  Brendan J Snellgrove; Tilman Steinert; Susanne Jaeger
Journal:  CNS Drugs       Date:  2017-10       Impact factor: 5.749

6.  Oxycodone-induced tolerance to respiratory depression: reversal by ethanol, pregabalin and protein kinase C inhibition.

Authors:  Rob Hill; William L Dewey; Eamonn Kelly; Graeme Henderson
Journal:  Br J Pharmacol       Date:  2018-05-07       Impact factor: 8.739

7.  Fatal toxicity index of medicinal drugs based on a comprehensive toxicology database.

Authors:  Ilkka Ojanperä; Pirkko Kriikku; Erkki Vuori
Journal:  Int J Legal Med       Date:  2016-03-17       Impact factor: 2.686

8.  Risk to heroin users of polydrug use of pregabalin or gabapentin.

Authors:  Abigail Lyndon; Suzanne Audrey; Claudia Wells; Erica S Burnell; Suzanne Ingle; Rob Hill; Matthew Hickman; Graeme Henderson
Journal:  Addiction       Date:  2017-05-15       Impact factor: 6.526

9.  Antiepileptic use for epilepsy and nonepilepsy disorders: A population-based study (1998-2013).

Authors:  Christine Leong; Muhammad M Mamdani; Tara Gomes; David N Juurlink; Erin M Macdonald; Marina Yogendran
Journal:  Neurology       Date:  2016-02-05       Impact factor: 9.910

Review 10.  Gabapentin misuse, abuse and diversion: a systematic review.

Authors:  Rachel V Smith; Jennifer R Havens; Sharon L Walsh
Journal:  Addiction       Date:  2016-03-18       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.